• Viatris reported positive top-line Phase 3 results for VR-205 in Japanese adults with primary IgA nephropathy.
• The trial met its main goal, showing meaningful improvement in protein leakage from the kidneys versus baseline.
• Secondary measures pointed to improved kidney function signals, with no patients reaching dialysis, transplant, or severe renal impairment during the study.
• The safety profile was consistent with prior global studies, supporting potential use in Japan.
• A Japan New Drug Application is targeted by end-2026; results were announced now, with no separate future presentation disclosed.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viatris Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202606290659PR_NEWS_USPR_____NE93437) on June 29, 2026, and is solely responsible for the information contained therein.